Group-specific Multi-allergen Sublingual/Swallow Immunotherapy Improves the Quality of Life of Polysensitized Children and Adults with Allergic Rhinitis

Background: The treatment of polysensitized allergic patients continues to represent a challenge and is a matter for debate amongst allergists who preferentially use allergen-specific immunotherapy. Objective: To study the effect of group-specific sublingual/swallow immunotherapy on quality of life of polysensitized human subjects with allergic rhinitis diagnosed using a comprehensive panel of cutaneous tests. Methods: 60 polysensitized subjects diagnosed with allergic rhinitis who submitted to group-specific sublingual/ swallow immunotherapy treatment corresponding to their cutaneous sensitizations, and who completed 6 months of treatment without the use of any complementary medication were evaluated with a validated quality of life questionnaire. Results: There were significant improvements in all quality of life categories evaluated, which included: sleep, systemic symptoms, practical problems, nasal symptoms, eye symptoms, activities and emotions. Conclusions: The administration of a group-specific multi-allergen sublingual/swallow immunotherapy as indicated by a comprehensive panel of sensitizing agents in cutaneous tests performed by a specialized team, significantly improved the quality of life of human polysensitized subjects with allergic rhinitis without the use of any additional medication.